Table 1. An overview of the included studies.
LAI: long-acting injectible
| Serial No.. | Study | Title and year published | Journal | Sample size | LAIs used | Outcomes |
| 1. | Sung Wan et al. [3] | Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia (2007) | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 1 | Risperidone LAI | No adverse outcomes reported |
| 2. | Orsolini et al. [4] | Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long-acting injectable antipsychotics (2021) | Expert Opinion on Drug Safety | 11 | Five patients received aripiprazole; one patient received olanzapine; three patients received risperidone; two patients received paliperidone | Three preterm vaginal deliveries |
| 3. | Fernandez- Abascal et al. [5] | Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report (2021) | Therapeutic Advances in Psychopharmacology | 6 | Aripiprazole; one woman interrupted LAI treatment at the end of the first trimester | No adverse outcomes reported |
| 4. | Nguyen et al. [6] | Long-acting injectable antipsychotic treatment during pregnancy: outcomes for women at a tertiary maternity hospital (2022) | Psychiatry Research | 36 | One patient received haloperidol; two patients received fluphenazine; nine patients received flupenthixol; 12 patients received zuclopenthixol; eight patients received aripiprazole; two patients received paliperidone; four patients received risperidone | Six preterm vaginal deliveries |
| 5. | Eleftheriou et al. [1] | Long-acting injectable antipsychotic treatment during pregnancy: a case series (2023) | International Journal of Environmental Research and Public Health | 15 | Five patients received paliperidone; 10 patients received aripiprazole | two miscarriages; one still-birth; one preterm vaginal delivery |
| 6. | Ballester-Garcia et al. [7] | Use of long-acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report (2023) | BMC Pharmacology and Toxicology | 1 | Aripiprazole | No adverse outcomes reported |